Company Overview
Celularity Inc. operates as a regenerative and cellular medicines company dedicated to addressing aging-related and degenerative diseases through the development of off-the-shelf placental-derived allogeneic cell therapy product candidates. The company specifically focuses on therapeutic applications for diabetic foot ulcers and Crohn's disease, utilizing mesenchymal-like adherent stromal cells as its primary product candidates. This entity functions within the healthcare sector, specifically classified under the biotechnology industry, which implies a focus on research and development of biological products rather than manufacturing or consumer goods. The company maintains a market capitalization of $35.18M, reports annual revenue of $40.58M, and employs 123 individuals to support its operations. These financial figures indicate that Celularity is a small-cap biotechnology firm with a revenue base that significantly exceeds its market valuation, suggesting a company in a growth or development phase where future potential is priced in rather than current profitability. The disparity between the $40.58M revenue and the $35.18M market cap further highlights the speculative nature often associated with pre-commercial biotech assets that rely on regulatory approval pathways before generating substantial profits.
Financial Health
The company reports a trailing twelve-month revenue of $40.58M, yet it simultaneously posts a net income of $-80,647,000 and an EBITDA of $-41,355,000. The substantial gap between the positive revenue of $40.58M and the negative net income reveals a cost structure characterized by high operating expenses that exceed total sales, a common trait in early-stage biotechnology development. Despite the negative earnings, the company maintains a free cash flow of $12.79M, which indicates a degree of financial flexibility allowing it to fund operations without immediate external capital injections. However, this liquidity is constrained by a cash balance of only $120,000 against total debt obligations of $66.76M. The analysis of the three profit margins shows a gross margin of 50.6%, an operating margin of -243.2%, and a profit margin of -198.7%; the wide divergence between the healthy gross margin and deeply negative operating and profit margins suggests significant overhead costs related to research, development, or administrative functions. When comparing total cash of $120,000 to total debt of $66.76M, the balance sheet appears highly leveraged and potentially precarious given the negative debt-to-equity ratio and the inability to service debt with existing liquid assets. The current ratio stands at 0.16, which indicates that the company possesses less than one dollar of current assets for every dollar of current liabilities, signaling tight short-term liquidity conditions. Furthermore, the return on equity is listed as N/A due to the capital structure, while the return on assets is -25.0%, revealing that management is currently destroying value relative to the assets employed in the business.
Valuation Assessment
The valuation metrics for Celularity Inc. include a trailing P/E ratio of N/A and a forward P/E of -2.14, the difference between these figures implies that the company is not currently profitable and future earnings estimates are negative or not yet realized. The price-to-book ratio is -1.71, which indicates that the market values the company at a negative premium over its book value, reflecting the accounting reality of accumulated losses or intangible asset impairments. Alternative valuation metrics such as the price-to-sales ratio of 0.87 and an EV/EBITDA of -2.45 provide a different perspective, suggesting the stock trades at less than one dollar of sales, which is typical for non-profitable biotech firms but highlights the risk of the asset base. Regarding the price range, the 52-week high is $4.35 and the 52-week low is $1.01, meaning the current price sits within a range where the asset has experienced significant volatility but remains below the peak valuation of the period. The beta value is 0.79, which means the stock price volatility is lower than the broader market, moving less aggressively than the S&P 500 during market swings.
Growth & Income
The revenue growth year-over-year is -43.2%, while the earnings growth year-over-year is N/A, indicating that the company is contracting in terms of sales rather than expanding. Since earnings growth is not applicable due to the lack of profitability, it is impossible to determine if earnings are growing faster or slower than revenue, but the negative revenue growth implies a shrinking top line and potential challenges in maintaining market share or commercializing products. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm reinvests any available earnings or utilizes cash reserves into growth initiatives rather than distributing income to shareholders. This reinvestment strategy is necessary for a company with negative net income and high debt, as paying dividends would be unsustainable given the financial constraints. The overall growth and income profile is characterized by negative revenue expansion and no income distribution, reflecting a high-risk, high-potential trajectory typical of small-cap biotechnology companies seeking commercial validation.